Equities Analysts Issue Forecasts for Syneos Health Inc’s Q1 2019 Earnings (NASDAQ:SYNH)

Syneos Health Inc (NASDAQ:SYNH) – Stock analysts at William Blair issued their Q1 2019 EPS estimates for Syneos Health in a research report issued on Tuesday, March 19th, Zacks Investment Research reports. William Blair analyst J. Kreger expects that the company will earn $0.50 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Syneos Health’s Q2 2019 earnings at $0.62 EPS, Q3 2019 earnings at $0.76 EPS, Q4 2019 earnings at $0.84 EPS, FY2019 earnings at $2.72 EPS, Q1 2020 earnings at $0.72 EPS, Q2 2020 earnings at $0.75 EPS, FY2020 earnings at $3.13 EPS and FY2021 earnings at $3.54 EPS.

Several other analysts have also issued reports on SYNH. ValuEngine lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research report on Saturday. Wolfe Research initiated coverage on shares of Syneos Health in a research report on Tuesday, April 2nd. They issued a “market perform” rating for the company. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research report on Saturday, December 29th. Credit Suisse Group upped their price target on shares of Syneos Health from $49.00 to $51.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 19th. Finally, Barclays dropped their price target on shares of Syneos Health from $51.00 to $45.00 and set an “equal weight” rating for the company in a research report on Thursday, January 3rd. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $52.70.

NASDAQ SYNH traded down $0.17 during trading hours on Friday, hitting $49.89. 564,671 shares of the company’s stock traded hands, compared to its average volume of 755,908. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.97. The firm has a market capitalization of $5.19 billion, a price-to-earnings ratio of 19.04, a price-to-earnings-growth ratio of 1.43 and a beta of 1.45. Syneos Health has a 52 week low of $36.26 and a 52 week high of $56.34.

Syneos Health (NASDAQ:SYNH) last announced its earnings results on Monday, March 18th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.16. The company had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. Syneos Health had a net margin of 0.55% and a return on equity of 9.60%. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.70 earnings per share.

Several hedge funds have recently added to or reduced their stakes in SYNH. Enlightenment Research LLC purchased a new stake in Syneos Health during the fourth quarter valued at $51,000. NumerixS Investment Technologies Inc purchased a new stake in Syneos Health during the fourth quarter valued at $57,000. Bessemer Group Inc. purchased a new stake in Syneos Health during the fourth quarter valued at $59,000. Oppenheimer Asset Management Inc. purchased a new stake in Syneos Health during the fourth quarter valued at $66,000. Finally, Private Capital Group LLC raised its stake in Syneos Health by 79.7% during the fourth quarter. Private Capital Group LLC now owns 1,824 shares of the company’s stock valued at $72,000 after purchasing an additional 809 shares in the last quarter.

In other news, CEO Alistair Macdonald sold 6,697 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $53.04, for a total value of $355,208.88. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is currently owned by insiders.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Read More: What does EPS mean?

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.